WHAT YOU NEED TO KNOW BY THE NUMBERS – A new Morning Consult poll conducted for the Campaign for Sustainable Rx Pricing (CSRxP) – a member of CAPA – found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform the U.S. healthcare system to lower costs and put […]

Continue Reading

WASHINGTON, D.C. – The Coalition Against Patent Abuse (CAPA) – a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others – issued a statement today following the release of a Morning Consult survey which found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform […]

Continue Reading

Part I: IPR & Insulin – The True Value of PTAB Proceedings Year after year, pharmaceutical companies engage in anticompetitive strategies to game the U.S. patent system and keep drug prices high at the expense of patients. Even as millions of Americans grapple with financial hardships brought on by the COVID-19 pandemic, these pharmaceutical companies […]

Continue Reading

WHAT YOU NEED TO KNOW MUST READ: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), recently authored an op-ed in Bloomberg Law around the Federal Circuit’s recent decision in GlaxoSmithKline LLCTeva Pharmaceuticals USA, Inc.: “The Federal Circuit’s decision in GlaxoSmithKline […]

Continue Reading

IN CASE YOU MISSED IT: Today, Bloomberg Law published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), around the Federal Circuit’s recent decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. which undermines the ‘skinny label’ framework used by generic drug companies to describe their products as therapeutically equivalent to branded drugs.   In his op-ed, […]

Continue Reading

In case you missed it, please see the piece below in today’s Washington Post by two leading experts from Brigham and Women’s Hospital/Harvard Medical School that outlines how a Biden White House could take immediate steps address rising drug prices for patients and families by fixing our patent system….. Biden can lower drug prices without […]

Continue Reading